ftInvstr
GLENMARK · Healthcare ₹2428.2 -1.25% Mkt Cap ₹68303 Cr

GLENMARK

Healthcare Drug Manufacturers - Specialty & Generic
₹2428.2
-1.25% today · 30d +7.69%
as of 2026-09-04
Price · Daily Candles
“Glenmark surges with Q4 profit jump, but FIIs pare holdings amid high valuation.”
Glenmark Pharmaceuticals reported a robust Q4 2025 with revenue up 15.15% YoY to ₹3901 Cr and net profit increasing 15.86% YoY to ₹403 Cr. However, its TTM PE of 62.49 is significantly above the sector average, and the company is currently free-cash-flow negative at -2.38% of market cap.
BULL CASE
+Glenmark's net profit saw a strong 15.86% YoY increase in Q4 2025, reaching ₹403 Cr.
+Quarterly revenue grew 15.15% YoY to ₹3901 Cr in Q4 2025.
+The 1-year return stands at 64.25%, with the stock trading near its 52-week high of ₹2474.0, indicating strong recent momentum.
+Despite being free-cash-flow negative, ML predictions for 1-year sales growth are strong, with a recent 2-year rank of 0.814, rolling 4-year rank of 0.85, and stable 7-year rank of 0.868.
BEAR CASE
The stock is trading at a TTM PE of 62.49, significantly higher than peers like Dr. Reddy's (19.55) and Cipla (29.52).
Glenmark is currently free-cash-flow negative, with a FCF yield of -2.38% of its market cap.
FIIs decreased their holding by 1.14% QoQ to 20.34% in Q4 2026, while DIIs also reduced their stake by 0.8% to 19.29%.
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹4018 Cr
+23.1% YoY
NET PROFIT
₹483 Cr
+927.88% YoY
OPM
21.32%
+2.87pp YoY
EPS
₹17.11
PE 62.49
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-18.0%, h2=-20.1%, h3=-18.9% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Glenmark's TTM PE of 62.49 is notably higher than sector leaders like Sun Pharma (40.41 PE, 22.46% ROCE) and Dr. Reddy's (19.55 PE, 27.63% ROCE), positioning it as a pricier option despite a ROCE of 19.0%.
PEERPEROCE %
GLENMARK62.4919.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
71
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 90
Valuation STRETCHED 20
Growth STRONG 88
Profitability HIGH 78
Technicals STRONG 72
Risk LOW 80
Key Stats
TTM PE
62.49
P/B
6.92
52W HIGH
₹2537.6
OFF HIGH
-4.31%
DIV YIELD
0.21%
MKT CAP
₹68303 Cr
◉ Active Signals
MACDBullish4.8696
RSI(14)Neutral57.96
Near 52W HighBullish-4.31
Street Consensus
11 analysts
₹2227.36
mean target
Low ₹1500.0Now ₹2428.2High ₹2735.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold GLENMARK and at what entry.

Sign up freeSign in